Novo Nordisk’s ousting of longtime CEO Lars Fruergaard Jørgensen bemused analysts, with many questioning the future of the Wegovy obesity drug maker.
Source link
Trending
- Retail investors bought the most stocks for a morning ever on Monday after Moody’s downgrade
- Trump allows New York offshore wind project after gas compromise
- D-Wave Quantum releases latest computing system
- Bernstein raises its price target on this stock with a ‘history of momentum’
- JPMorgan’s 2025 summer reading list
- Goldman Sachs hikes Microsoft price target, sees AI investments driving strong growth
- Home Depot (HD) Q1 2025 earnings
- Chinese businesses are moving away from the U.S. despite trade truce
Novo Nordisk's future in doubt after Wegovy maker's 'surprise' CEO ouster
